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LETTERS TO THE EDITOR
Antiretroviral drugs and the
kidney: Further precisions
To the Editor: We read with interest the excellent arti-
cle of Daugas et al [1] on HAART-related nephropathies
and we would like to clarify several points.
There has been no case report of Fanconi syndrome
(FS) related to reverse transcriptase inhibitors (RTIs)
except one induced by didanosine [2]. Actually, the sus-
pected case of nevirapine-induced FS was largely related
to lactic acidosis rather than renal tubular acidosis, con-
sidering the anion gap that was increased [3].
It is speculative to incriminate enfuvirtide as a poten-
tial cause of membranoproliferative glomerulonephritis
(MPGN). Indeed, the diagnosis of MPGN was made on
a renal biopsy performed after 57 days of enfuvirtide
therapy together with tenofovir, lamivudine, lopinavir-
ritonavir, amprenavir, and efavirenz, and in a patient
with a history of diabetes and seasonal allergies. Further-
more, in this patient, renal abnormalities (proteinuria and
hematuria) were already present before enfuvirtide was
started [4].
Finally, the entire chapter on nucleotide reverse tran-
scriptase inhibitors (NtRTIs) is confusing with regard to
adefovir potential renal toxicity. Effectively, it is crucial
to specify that at its normal dosage of 10 mg daily for the
treatment of (hepatitis B virus) HBV infection, adefovir
is not nephrotoxic [5]. Furthermore, cidofovir at 3 mg/kg
for BK virus infection has also been reported not to be
nephrotoxic [6].
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Hypotonic fluids should not be
used in volume-depleted
children
To the Editor: Dr. Friedman recommends that dehy-
drated children requiring intravenous therapy should re-
ceive hypotonic fluids with a sodium concentration of
3 mEq per 100 ml, after initially receiving bolus ther-
apy with isotonic fluid [1]. A recent report revealed that
many children treated in this fashion developed acute hy-
ponatremia [2]. Dr. Friedman is also incorrect when stat-
ing that most cases of hospital-acquired hyponatremia
resulted when “maintenance therapy was applied erro-
neously.” By Dr. Friedman’s own calculations, 0.45%
sodium chloride would be used for the treatment of
dehydration according to the deficit therapy approach.
Dr. Friedman offers no data to support the safety of us-
ing hypotonic fluid in volume-depleted children. It makes
no physiologic sense to administer hypotonic fluids to
patients with a hemodynamic stimulus for vasopressin
production.
The recommendations of using 3 mEq of sodium chlo-
ride per 100 mL of parenteral fluids are based on the
sodium content of human and cow milk [3]. This is far
less than the sodium content in the standard American
diet and has no applicability to the hospitalized child who
may have impaired free water excretion. The safety of
this approach has never been demonstrated in the hos-
pitalized children. What we do know is that there have
been numerous deaths resulting from hypotonic fluid ad-
ministration, prompting us to recommend the use of 0.9%
sodium chloride in parenteral fluid as prophylaxis against
hospital-acquired hyponatremia [4]. Dr. Friedman is crit-
ical of our recommendations, stating that “high volumes”
of fluid could result in fluid overload. We have never
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